Kunshan RiboQuark Raises $7.5 Million For siRNA Projects
Published: Jan 10, 2014
by Richard Daverman, PhD
January 10, 2014 -- Kunshan RiboQuark Pharma, a siRNA joint venture formed by Suzhou Ribo Life Science and Quark Pharma of California, raised almost 45 million RMB ($7.5 million) in a series A round. The financing was led by BVCF, formerly known as BioVeda China. RiboQuark will use the money to further clinical development of QPI-1007, a siRNA ocular neuroprotectant developed by Quark for which the JV owns China rights. More details....
Help employers find you! Check out all the jobs and post your resume.